Dow Jones -- U.K.-based pharmaceuicals company GlaxoSmithKline PLC (GSK) has signed an exclusive license agreement with Apeiron Biologics to acquire the Austrian biotech company's rights to an early-stage lung disease drug, Apeiron said Wednesday. Under the deal, the world's second-largest drugmaker will get exclusive rights to APN01, an experimental medicine in Phase I development for the treatment of acute respiratory distress syndrome.
